What is Haemonetics's medsurg — SG&A?

Haemonetics (HAE) reported medsurg — SG&A of $65.16M in Q2 2026.

What does medsurg — SG&A mean?

Captures the indirect operating expenses required to support the MedSurg segment, including sales force compensation, marketing, and corporate overhead allocations. This metric helps assess the segment's operational leverage and cost management discipline.

Haemonetics (HAE) MedSurg — SG&A

Screener

Other segment segments

Apheresis

$44.26M—

Similar metrics at other companies

LENCentral — SG&A

$148.21M-2.7%

LENEast — SG&A

$162.77M+0.4%

LENHomebuilding — SG&A

$617.5M+0.3%

LENOther — SG&A

$7.71M+91.6%

LENWest — SG&A

$191.17M-5.5%

COSTCanada — SG&A

$2.2B+11.3%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025
Apheresis operating income	$56,545	$59,175
MedSurg
Cost of goods sold	$50,368	$50,216
Selling, general and administrative	65,160	62,323
Research and development	9,820	8,742
MedSurg operating income	$22,714	$18,377
Corporate and unallocated expenses
Amortization of acquired assets	$(10,204)	$(13,828)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's medsurg — SG&A?: Haemonetics (HAE) reported medsurg — SG&A of $65.16M in Q2 2026.
What does medsurg — SG&A mean?: Captures the indirect operating expenses required to support the MedSurg segment, including sales force compensation, marketing, and corporate overhead allocations. This metric helps assess the segment's operational leverage and cost management discipline.